Seer (SEER) Days Sales Outstanding : 130.19 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Seer Days Sales Outstanding?

Seer's average Accounts Receivable for the three months ended in Mar. 2024 was $4.32 Mil. Seer's Revenue for the three months ended in Mar. 2024 was $3.03 Mil. Hence, Seer's Days Sales Outstanding for the three months ended in Mar. 2024 was 130.19.

The historical rank and industry rank for Seer's Days Sales Outstanding or its related term are showing as below:

SEER' s Days Sales Outstanding Range Over the Past 10 Years
Min: 84.63 Med: 109.94 Max: 142.43
Current: 117.67

During the past 6 years, Seer's highest Days Sales Outstanding was 142.43. The lowest was 84.63. And the median was 109.94.

SEER's Days Sales Outstanding is ranked worse than
71.96% of 895 companies
in the Biotechnology industry
Industry Median: 72.67 vs SEER: 117.67

Seer's Days Sales Outstanding increased from Mar. 2023 (111.06) to Mar. 2024 (130.19).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Seer Days Sales Outstanding Historical Data

The historical data trend for Seer's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seer Days Sales Outstanding Chart

Seer Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

142.43

84.63

109.94

Seer Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															111.06	121.29	119.41	112.68	130.19

Competitive Comparison of Seer's Days Sales Outstanding

For the Biotechnology subindustry, Seer's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seer's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seer's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Seer's Days Sales Outstanding falls into.

Seer Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Seer's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (4.315	+	4.831)	/	2 )	/	15.182	*	365
=	4.573					/	15.182	*	365
=	109.94

Seer's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (4.831	+	3.815)	/	2 )	/	3.03	*	365 / 4
=	4.323					/	3.03	*	365 / 4
=	130.19

Seer (NAS:SEER) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Seer Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Seer's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Seer (SEER) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seer Inc (NAS:SEER) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3800 Bridge Parkway, Suite 102, Redwood City, CA, USA, 94065

Website

https://www.seer.bio

Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.

Executives

Elona Esq. Kogan	officer: General Counsel and Secretary	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omid Farokhzad	director, 10 percent owner, officer: CEO and Chair of the Board	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Scott D Thomas	officer: Chief Commercial Officer	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
David R. Horn	officer: Chief Financial Officer	3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omead Ostadan	director, officer: President & COO	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Meeta Gulyani	director	C/O SEER, INC., 3800 BRIDGEPOINT PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Rachel E. Haurwitz	director	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Maverick Ventures Investment Fund, L.p.	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Capital Ventures, Llc	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Advisors Fund, L.p.	director	300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
David Hallal	director	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Terrance Mcguire	director	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
David B Singer	director	C/O MAVERICK CAPITAL, LTD., 101 CALIFORNIA STREET, SUITE 4015, SAN FRANCISCO CA 94111
Cathy Friedman	director	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005